What is B. Riley's Forecast for Vaxart FY2029 Earnings?

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Stock analysts at B. Riley issued their FY2029 earnings per share (EPS) estimates for Vaxart in a research note issued to investors on Thursday, May 29th. B. Riley analyst M. Mamtani anticipates that the biotechnology company will post earnings per share of $0.13 for the year. B. Riley has a "Buy" rating and a $2.00 price target on the stock. The consensus estimate for Vaxart's current full-year earnings is ($0.39) per share.

Separately, Wall Street Zen upgraded Vaxart to a "hold" rating in a report on Thursday, May 22nd.

Vaxart Stock Down 7.0%

Vaxart stock traded down $0.03 during mid-day trading on Friday, reaching $0.42. 1,075,815 shares of the company's stock were exchanged, compared to its average volume of 2,431,780. The business's fifty day simple moving average is $0.40 and its 200 day simple moving average is $0.56. The firm has a market capitalization of $95.49 million, a PE ratio of -1.02 and a beta of 1.27. Vaxart has a one year low of $0.29 and a one year high of $1.07.

Vaxart (NASDAQ:VXRT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). The business had revenue of $20.88 million for the quarter, compared to analyst estimates of $2.85 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.

Insider Buying and Selling at Vaxart

In related news, insider Steven Lo purchased 100,000 shares of Vaxart stock in a transaction dated Monday, May 19th. The stock was bought at an average cost of $0.49 per share, for a total transaction of $49,000.00. Following the completion of the transaction, the insider now owns 100,000 shares in the company, valued at $49,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.90% of the company's stock.

Institutional Trading of Vaxart

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 17,942 shares during the period. Invesco Ltd. raised its stake in shares of Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 24,803 shares during the period. Graham Capital Management L.P. raised its stake in shares of Vaxart by 155.8% during the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 32,482 shares during the period. Sequoia Financial Advisors LLC raised its stake in shares of Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 35,213 shares during the period. Finally, Geode Capital Management LLC grew its position in Vaxart by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock worth $1,723,000 after buying an additional 57,911 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.